The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor α mediated liver disease

Frelin, L.; Brenndörfer, E. D.; Ahlén, G.; Weiland, M.; Hultgren, C.; Alheim, M.; Glaumann, H.; Rozell, B.; Milich, D. R.; Bode, J. G.; Sällberg, M.
October 2006
Gut;Oct2006, Vol. 55 Issue 10, p1475
Academic Journal
Background: The hepatitis C virus (HCV) establishes chronic infection by incompletely understood mechanisms. The non-structural (NS) 3/4A protease/helicase has been proposed as a key complex in modulating the infected hepatocyte, although nothing is known about the effects this complex exerts in vivo. Aim: To generate mice with stable and transient hepatocyte expression of the HCV NS3/4A proteins to study its effects in vivo. Methods: NS3/4A expression was determined by western blot and immunohistochemistry. Two independent pathologists determined the liver histology. Hepatic immunity was characterised by quantifying intrahepatic immune cell subsets. Liver damage was induced using carbon tetrachloride (CCI4), lipopolysaccaride (LPS), tumour necrosis factor α (TNFα), and anti-Fas antibody. Results: Expression of NS3/4A was restricted to the cytoplasm of hepatocytes, and did not cause liver cancer or any spontaneous liver pathology. However, the presence of NS3/4A modulated the intrahepatic immunity, as follows: first, the CD4+ T cell and type I/II dendritic cell subsets were reduced in transgenic livers; second, NS3/4A protected hepatocytes from liver damage mediated in vivo by CCl4, LPS, TNFα, but not FAS; and third, both stable and transiently NS3/4A transgenic mice were resistant to lethal doses of liver targeted TNFα, and the resistance could be reverted by treatment with a p38 mitogen activated protein kinase inhibitor (MAPK). Conclusions: Hepatic expression of NS3/4A does not induce spontaneous liver disease. NS3/4A does, however, alter the intrahepatic immune cell subsets and protects hepatocytes against TNFα induced liver damage in vivo. The TNFα resistance can be reverted by treatment with a p38 MAPK inhibitor. This represents a new immune evasion strategy conferred by NS3/4A.


Related Articles

  • Demonstration of the Presence of the “Deleted” MIR122 Gene in HepG2 Cells. Hamad, Ibrahim A. Y.; Fei, Yue; Kalea, Anastasia Z.; Yin, Dan; Smith, Andrew J. P.; Palmen, Jutta; Humphries, Steve E.; Talmud, Philippa J.; Walker, Ann P. // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    MicroRNA 122 (miR-122) is highly expressed in the liver where it influences diverse biological processes and pathways, including hepatitis C virus replication and metabolism of iron and cholesterol. It is processed from a long non-coding primary transcript (~7.5 kb) and the gene has two...

  • Virology: Fresh assault on hepatitis C. Rice, Charles M. // Nature;11/13/2003, Vol. 426 Issue 6963, p129 

    The article focuses on research work related to Hepatitis C virus. As researchers gradually got to grips with viruses that attack the liver, two were identified early on as Hepatitis A and Hepatitis B. But Hepatitis C is a severe medical problem. The virus itself has a tiny genome, consisting of...

  • Hepatitis C virus E2 protein involve in insulin esistance through an impairment of Akt/PKB and GSK3β signaling in hepatocytes. Ming-Ju Hsieh; Kuang-Ping Lan; Hao-Yu Liu; Xiao-Zong Zhang; Yaw-Feng Lin; Tzy-Yen Chen; Hui-Ling Chiou // BMC Gastroenterology;2012, Vol. 12 Issue 1, p74 

    Background: Hepatitis C virus (HCV) infection may cause liver diseases of various severities ranging from primary acute infection to life-threatening diseases, such as cirrhosis or hepatocellular carcinoma with poor prognosis. According to clinical findings, HCV infection may also lead to some...

  • Allosteric Inhibitors of the NS3 Protease from the Hepatitis C Virus. Abian, Olga; Vega, Sonia; Sancho, Javier; Velazquez-Campoy, Adrian // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    The nonstructural protein 3 (NS3) from the hepatitis C virus processes the non-structural region of the viral precursor polyprotein in infected hepatic cells. The NS3 protease activity has been considered a target for drug development since its identification two decades ago. Although specific...

  • Hepatocyte nuclear factor 4a controls the development of a hepatic epithelium and liver morphogenesis. Parviz, Fereshteh; Matullo, Christine; Garrison, Wendy D; Savatski, Laura; Adamson, John W; Ning, Gang; Kaestner, Klaus H; Rossi, Jennifer M; Zaret, Kenneth S; Duncan, Stephen A // Nature Genetics;Jul2003, Vol. 34 Issue 3, p292 

    Although advances have been made in understanding cell differentiation, only rudimentary knowledge exists concerning how differentiated cells form tissues and organs. We studied liver organogenesis because the cell and tissue architecture of this organ is well defined. Approximately 60% of the...

  • The GB Virus C (GBV-C) NS3 Serine Protease Inhibits HIV- 1 Replication in a CD4+ T Lymphocyte Cell Line without Decreasing HIV Receptor Expression. George, Sarah L.; Varmaz, Dino; Tavis, John E.; Chowdhury, Adnan // PLoS ONE;Jan2012, Vol. 7 Issue 1, p1 

    Introduction: Persistent infection with GBV-C (GB Virus C), a non-pathogenic virus related to hepatitis C virus (HCV), prolongs survival in HIV infection. Two GBV-C proteins, NS5A and E2, have been shown previously to inhibit HIV replication in vitro. We investigated whether the GBV-C NS3 serine...

  • Protease Inhibitors for Hepatitis C: Economic Implications. Turner, Stuart; Brown, Jack; Paladino, Joseph // PharmacoEconomics;Sep2013, Vol. 31 Issue 9, p739 

    Chronic hepatitis C virus (HCV) infection, a blood-borne virus, is the leading cause of chronic liver disease and liver transplantation worldwide. Chronic HCV infection is usually asymptomatic in the early stages of the disease, making an estimation of the total population affected difficult to...

  • The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors. Romano, Keith P.; Ali, Akbar; Aydin, Cihan; Soumana, Djade; Özen, Ayşegül; Deveau, Laura M.; Silver, Casey; Hong Cao; Newton, Alicia; Petropoulos, Christos J.; Wei Huang; Schiffer, Celia A. // PLoS Pathogens;Jul2012, Vol. 8 Issue 7, Special section p1 

    Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including cirrhosis, liver failure, and liver cancer. Available antiviral therapies cause severe side effects and are effective only for a subset of patients, though treatment...

  • Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Scheel, Troels K H; Rice, Charles M // Nature Medicine;Jul2013, Vol. 19 Issue 7, p837 

    More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has paved the way for the development of antiviral compounds to spare patients from life-threatening liver disease. An...


Read the Article


Sign out of this library

Other Topics